Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.15580
Abstract: Key Points Question What are the risks of venous thromboembolism (VTE) after lower extremity revascularization (LER) for peripheral artery disease (PAD), and is use of low-dose rivaroxaban plus aspirin associated with risk of VTE after… read more here.
Keywords: lower extremity; venous thromboembolism; peripheral artery; risk ... See more keywords
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA neurology"
DOI: 10.1001/jamaneurol.2021.3828
Abstract: Importance It is uncertain whether anticoagulation is superior to aspirin at reducing recurrent stroke in patients with recent embolic strokes of undetermined source (ESUS) and left ventricular (LV) dysfunction. Objective To determine whether anticoagulation is… read more here.
Keywords: trial; rivaroxaban; dysfunction; aspirin ... See more keywords
Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of hematology"
DOI: 10.1002/ajh.26945
Abstract: The benefit of rivaroxaban in thromboprophylaxis after oncologic lung surgery remains unknown. To evaluate the efficacy and safety of rivaroxaban, patients who underwent thoracic surgery for lung cancer were enrolled, and randomly assigned to rivaroxaban… read more here.
Keywords: thromboprophylaxis; surgery; thoracic surgery; lung ... See more keywords
Favorable effect of rivaroxaban against vascular dysfunction in diabetic mice by inhibiting NLRP3 inflammasome activation
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.30807
Abstract: Cardiovascular disease (CVD) is the leading cause of death in various complications of type 2 diabetes mellitus (T2DM). Rivaroxaban (Xarelto; Bayer), an oral direct factor Xa (FXa) inhibitor, prevents the activation of the coagulation cascade… read more here.
Keywords: vascular dysfunction; dysfunction; mice; rivaroxaban ... See more keywords
Population Pharmacokinetics of Rivaroxaban In Real-World Patients.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2255
Abstract: The pharmacokinetics of rivaroxaban have been studied in different populations, and there were differences in the pharmacokinetic parameters. However, most of these studies were conducted on healthy subjects from different ethnic groups. Thus, this study… read more here.
Keywords: pharmacokinetics rivaroxaban; rivaroxaban real; world patients; rivaroxaban ... See more keywords
Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-019-01986-8
Abstract: Several real-world studies have evaluated adherence to direct acting oral anticoagulants in patients with non-valvular atrial fibrillation (NVAF); however, these studies have not been systematically summarized. We performed a meta-analysis to compare adherence to rivaroxaban… read more here.
Keywords: real world; rivaroxaban; dabigatran; adherence ... See more keywords
Rivaroxaban for the treatment of cerebral venous thrombosis: a single-center experience.
Sign Up to like & getrecommendations! Published in 2021 at "Acta neurologica Belgica"
DOI: 10.1007/s13760-021-01651-z
Abstract: The mainstay of cerebral venous thrombosis (CVT) treatment according to current guidelines is parenteral anticoagulation with unfractionated heparin or low-molecular-weight heparin followed by long-term oral anticoagulation with vitamin K antagonists. Direct oral anticoagulants (DOACs), including… read more here.
Keywords: single center; venous thrombosis; rivaroxaban; cerebral venous ... See more keywords
Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-017-0540-1
Abstract: Background and Objective Venous thromboembolism (VTE), comprising deep-vein thrombosis (DVT) and pulmonary embolism (PE), is a major healthcare concern that results in substantial morbidity and mortality with great economic burden for healthcare systems. Hence, the… read more here.
Keywords: rivaroxaban; treatment; cost; dvt ... See more keywords
Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin
Sign Up to like & getrecommendations! Published in 2021 at "Drug Safety"
DOI: 10.1007/s40264-021-01072-0
Abstract: There have been reports of clinically relevant uterine bleeding events among women of reproductive age exposed to rivaroxaban. The aim of this study was to compare the risk of severe abnormal uterine bleeding (SAUB) resulting… read more here.
Keywords: risk; apixaban dabigatran; uterine bleeding; rivaroxaban ... See more keywords
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
Sign Up to like & getrecommendations! Published in 2017 at "American Heart Journal"
DOI: 10.1016/j.ahj.2016.10.017
Abstract: Background Optimal antithrombotic treatment after transcatheter aortic valve replacement (TAVR) is unknown and determined empirically. The direct factor Xa inhibitor rivaroxaban may potentially reduce TAVR‐related thrombotic complications and premature valve failure. Design GALILEO is an… read more here.
Keywords: rivaroxaban; design; tavr; aortic valve ... See more keywords
Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.
Sign Up to like & getrecommendations! Published in 2020 at "American heart journal"
DOI: 10.1016/j.ahj.2020.01.010
Abstract: BACKGROUND There is limited evidence on the effectiveness and safety of direct-acting oral anticoagulants in patients with nonvalvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD). This study compared the risks of ischemic stroke/systemic… read more here.
Keywords: atrial fibrillation; nonvalvular atrial; rivaroxaban; warfarin ... See more keywords